Follow us on Twitter
twitter icon@FreshPatents


Sleep Disorders patents

      

This page is updated frequently with new Sleep Disorders-related patent applications.




 Preparation for improving the action of receptors patent thumbnailPreparation for improving the action of receptors
The present invention relates to the use of polyunsaturated fatty acids and one or more components which have a beneficial effect on total methionine metabolism selected from the group consisting of vitamin b 12 and precursors thereof, vitamin b6 and derivatives thereof, folic acid, zinc and magnesium, in the manufacture of a preparation for improving the action of receptors. This preparation is advantageously applied in patients suffering from parkinson's disease, huntington's chorea, epilepsy, schizophrenia, paranoia, depression, sleep disorders, impaired memory function, psychoses, dementia and adhd..
N.v. Nutricia


 Monitoring of sleep phenomena patent thumbnailMonitoring of sleep phenomena
The present invention relates to method and a system for detecting sleep phenomena, the phenomena including at least one of sleep cycles and sleep disorders such as sleep apnea and hypopnea. Ballistocardiologic signals are detected from a subject person, which provide simultaneous information on heart rate variability (hvv) and stroke volume (sv) of the subject.
Murata Manufacturing Co., Ltd.


 Pde10 inhibitors and related compositions and methods patent thumbnailPde10 inhibitors and related compositions and methods
Isolated or pure compounds that inhibit pde10 are disclosed that have utility in the treatment of a variety of conditions, including but not limited to psychotic, anxiety, movement disorders and/or neurological disorders such as parkinson's disease, huntington's disease, alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, bell's palsy, cerebral palsy, sleep disorders, pain, tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided.
Omeros Corporation


 Micro- and nano-quantity sleep enhancing nutrient composition and  enhancing central nervous system protein clearance using same patent thumbnailMicro- and nano-quantity sleep enhancing nutrient composition and enhancing central nervous system protein clearance using same
The present invention relates to a dietary supplement, composition, nutraceutical, and/or system for inducing or treating biological responses or conditions (namely sleep or sleep disorders) which utilize ultra-low dosage amounts of vitamins, minerals, amino acids, co-enzymes, stimulants, and/or similar ingredients in a highly bio-active delivery system which bypasses first pass metabolism. In particular, the present invention relates to a nutraceutical composition/formulation which substantially bypasses first pass metabolism and such as, but not limited to, activation of the glymphatic system to facilitate clearance of neuronal metabolites from the csf and interstitial fluids in the brain..
Foundational Biosystems, Llc


 Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders patent thumbnailDoxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders
The invention relates to use of the cis-(z) isomer or isomeric mixtures containing specified ratios of the cis-(z) and trans-(e) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders. .
Procom One, Inc.


 Spiro-oxazolones patent thumbnailSpiro-oxazolones
The present invention provides spiro-oxazolones, which act as v1a receptor modulators, and in particular as v1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The present compounds are useful as therapeutics acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag..
Hoffmann-la Roche Inc.


 System and  detecting sleep disorders patent thumbnailSystem and detecting sleep disorders
An apparatus for detecting sleep disorders, such as obstructive sleep apnea, includes a housing insertable into an ear canal of a subject. A sensor disposed within the housing measures a position of the subject's head relative to an axis of gravity.

 Spiro-oxazolones patent thumbnailSpiro-oxazolones
The present invention provides spiro-oxazolones, which act as v1a receptor modulators, and in particular as v1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The present compounds are useful as therapeutics acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag..
Hoffmann-la Roche Inc.


 Flouro-naphthyl derivatives patent thumbnailFlouro-naphthyl derivatives
The compounds may be used for the treatment or prophylaxis of alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders.. .

 Automated, snore activated electro-mechanical mandibular advancement device patent thumbnailAutomated, snore activated electro-mechanical mandibular advancement device
An automated mandibular advancement device (mad) is described for the treatment of sleep disorders involving the occlusion of upper airway gas flow during sleep; one example being obstructive sleep apnea. In embodiments, a mad projects the lower jaw forward only after the patient has fallen asleep.

Peptides and pharmaceutical compositions for use in the treatment by nasal administration of patients suffering from anxiety and sleep disorders

The present invention provides peptides for use in a medicament which is administered nasally, wherein the peptide is an agonist of neuropeptide s receptor (npsr), of the receptor tgr23 and/or of vasopressin receptor-related receptor 1 (vrr1) or for use in the treatment of a patient by causing, promoting or increasing relieve or healing of phobic anxiety, avoidance anxiety, dis-sociative anxiety such as flashbacks, depersonalisation, derealisation, intrusions, vegetative symptoms related to anxiety symptoms, especially in panic attacks, in posttraumatic stress disorder, in generalised anxiety disorder and in anxiety accompanying depressive, or psychotic episodes, arousal, awakening, alertness, activity, spontaneous movement, an anxiolytic effect or a combination thereof in the patient, wherein the peptide is administered nasally or for use in the prophylaxis and/or treatment of an anxiety or sleep dis-order, especially in any type of hypersomnia like idiopathic hypersomnia, wherein the peptide is administered nasally. Further provided are pharmaceutical compositions for nasal administration comprising at least one of said peptides, uses of said peptide or said pharmaceutical composition.
Max-planck-gesellschaft Zur Forderung Der Wissenschaft E.v.

Delivery of drugs

The present invention relates to a composition comprising a hydrophilic drug and an amphiphilic carbohydrate compound for use in therapy wherein the composition is intranasally administered to the human or animal body. The composition can be used to treat a variety of disorders, including schizophrenia, obesity, pain and sleep disorders, psychiatric diseases, neurodegenerative conditions, brain cancers and infective diseases.
Nanomerics Ltd

Method and arrangement for alleviating the stress-related sleep disorder and reducing the stress level of a person

The invention relates to a method for resolving a person's sleep disorders by applying low frequency vibration to a part of the body, said method comprising the use of mechanical vibrators (1) present on a first side of a plate type base member (9) for setting the plate type base member (9) in vibration in such a way that is second surface transmits mechanical vibration, comprising a plurality of low frequency pulse trains (100) which are conducted to a part of the person's body. The successive pulse trains of mechanical vibration to be transmitted in the invention to a specific part of the body comprise both—a plurality of first successive pulse trains (100; 101, 102, 103 .
Oy Neurosonic Finland Ltd

Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators

Which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..

Humanized anti-acth antibodies and use thereof

The present invention is directed to antibodies and fragments thereof having binding specificity for acth. Embodiments of this invention relate to the binding fragments of antibodies described herein, comprising the sequences of the vh, vl and/or cdr polypeptides described herein, and the polynucleotides encoding them.
Alder Biopharmaceuticals, Inc.

Indol and indazol derivatives

The compounds may be used for the treatment or prophylaxis of alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders.. .

Pharmaceutical composition for treating or preventing neuropsychiatric disease, containing flavone-6-c-glucose derivatives as active ingredients

The present invention provides a pharmaceutical composition or a food composition comprising, as active ingredients, flavone-6-c-glucose derivatives or galenical extracts containing flavone-6-c-glucose derivatives. The composition of the present invention shows a functional effect of effectively treating or preventing cognitive dysfunction disorders such as delirium, dementia or amnesia, stroke, palsy, attention disorders, anxiety disorders or sleep disorders..
Dae Hwa Pharma. Co., Ltd.

Compositions comprising a dendrimer-resveratrol complex and methods for making and using the same

Compositions and pharmaceutical compositions including a dendrimer-resveratrol complex and methods for making and using the compositions are described herein. Methods of treating cancer, cardiovascular disease, cardiac failure, diabetes, alzheimer's disease, parkinson's disease and other brain diseases, fatty liver disease, obesity, cataracts, osteoporosis, muscle wasting, sleep disorders, acoustic trauma, inflammatory disease, psoriasis, arthritis, colitis, aging, viral disease, reproductive disease, and skin conditions or disorders including administering a therapeutically effective amount of the compositions to a subject in need are also provided.
Concordia University

Pyrrolopyridine or pyrazolopyridine derivatives

The compounds of the present invention are muscarinic m1 receptor positive allosteric modulators (pam) and hence are useful in the treatment of diseases, mediated by the muscarinic m1 receptor, such as alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders.. .

Glycine transporter inhibitor

Which are useful in the prevention or treatment of diseases such as schizophrenia, alzheimer's disease, cognitive impairment, dementia, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, acute stress disorder), depression, drug dependence, spasm, tremor, pain, parkinson's disease, attention deficit hyperactivity disorder, bipolar disorder, eating disorder, or sleep disorders, which is based on the glycine uptake-inhibiting action.. .

Pyrroloquinoline derivatives as 5-ht6 antagonists, preparation method and use thereof

This invention concerns pyrroloquinoline derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in schizophrenia, anxiety, depression, maniac depression, epilepsy, obsessive compulsive disorders, mood disorders, migraine, alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, panic attacks, attention deficit hyperactivity disorder, attention deficit disorder, parkinson's disease, huntington's disease, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, obesity and type-2 diabetes, functional bowel disorder, irritable bowel syndrome.
Universite De Montpellier

Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators, compositions, and their use

Wherein ring a, rq, -l-, r1, n, r2, and r3 are as defined herein. The compounds of the invention are useful as non-competitive mglur2 antagonists, or mglur2 negative allosteric modulators (nams), and in methods of treating a patient (preferably a human) for diseases or disorders in which the mglur2-nam receptor is involved, including potentially alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.

Agent for the treatment and prevention of sleep disorders

The invention relates to the fields of pharmaceutics and medicine and describes an agent for the treatment and prevention of sleep disorders, wherein a conjugate of glycine immobilized on detonation nanodiamond particles 2-10 nm in size comprises 21±3 wt. % glycine.

Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators, compositions, and their use

Wherein ring a, rq, -l-, r1, n, r2, and r3 are as defined herein. The compounds of the invention are useful as non-competitive mglur2 antagonists, or mglur2 negative allosteric modulators (nams), and in methods of treating a patient (preferably a human) for diseases or disorders in which the mglur2-nam receptor is involved, including potentially alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.

Glycine transporter inhibitor

Which are useful in the prevention or treatment of diseases such as schizophrenia, alzheimer's disease, cognitive impairment, dementia, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, acute stress disorder), depression, drug dependence, spasm, tremor, pain, parkinson's disease, attention deficit hyperactivity disorder, bipolar disorder, eating disorder, or sleep disorders, which is based on the glycine uptake-inhibiting action.. .

19-nor c3, 3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof

Provided herein are 19-nor c3,3-disubstituted c21-pyrazolyl steroids of formula (i), and pharmaceutically acceptable salts thereof; wherein-, r1, r2, r3a, r3b, r4a, r4b, r5, r6, and r7 are as defined herein. Such compounds are contemplated useful ni for the prevention and treatment of a variety of cns-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus..

Botulinum toxin for primary disorders of mood and affect using neurotransmitter cns imaging studies

The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety, and sleep disorders and cns disorders comprising the administration of a neurotoxin.. .
Botulinum Toxin Research Associates, Inc.

19-nor neuroactive steroids and methods of use thereof

Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to formula (i): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of cns-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, tinnitus, and status epilepticus..
Sage Therapeutics, Inc.

19-nor c3, 3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof

Provided herein are 19-nor c3,3-disubstituted steroids of formula (i): and pharmaceutically acceptable salts thereof; wherein, , r1, r2, r3a, r3b, r4a, and r4b are as defined herein, and a is a carbon bound substituted or unsubstituted 5- to 6-membered heteroaryl ring as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of cns-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus..
Sage Therapeutics, Inc.

Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto

Pyrazole derivatives of formula (ia) and pharmaceutical compositions thereof that modulate the activity of the serotonin 5ht2a receptor. Formula (ia).
Arena Pharmaceuticals, Inc.

Quinoline amide m1 receptor positive allosteric modulators

The present invention is directed to quinoline amide compounds of formula (i) which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositious comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..
Merck Sharp & Dohme Corp.

19-nor neuroactive steroids and methods of use thereof

Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to formula (i): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of cns-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, tinnitus, status epilepticus..

Composition of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto

The present invention relates to certain compositions of a 5-ht2a serotonin receptor modulator and methods for their preparation. The compositions disclosed herein are useful for increasing slow wave sleep, improvise sleep consolidation, improving sleep maintenance and improving sleep quality, and for treating insomnia and related sleep disorders, dyssomnias, parasomnias and nonrestorative sleep and the like.
Arena Pharmaceuticals

Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy

Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gammahydroxybutyrate that are also resistant to the conversion into gbl.
Jazz Pharmaceuticals, Inc.

Imidazolidinedione derivatives

The invention provides a compound of formula (ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of kv3.1 and/or kv3.2, and in the treatment of diseases or disorders where a modulator of kv3.1 and/or kv3.2 is required, such as depression and mood disorders, hearing disorders, schizopherenea, substance abuse disorders, sleep disorders or epilepsy..
Autifony Therapeutics Limited

Gamma-hydroxybutyrate compositions and their use for the treatment of disorders

Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (ghb). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus..
Jazz Pharmaceuticals Ireland Limited

Substituted benzimidazoles as nociceptin receptor modulators

The invention provides modulators of the nociceptin receptor (nop), including both agonists and antagonists. A compound of the invention can be a selective modulator of nop with respect to the μ- and κ-opioid receptors (mop and kop), thus providing a therapeutic method for the treatment of conditions wherein selective nop modulation is medically indicated and mop or kop modulation may be less desirable.
The Scripps Research Institute

Botulinum toxin and the treatment of primary disorders of mood and affect

The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety and sleep disorders and cns disorders comprising the administration of a neurotoxin.. .
Botulinum Toxin Research Associates, Inc.

Methods and compositions for sleep disorders and other disorders

Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-ht2a, sert and/or dopamine d2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or parkinson's disease or any combinations..
Intra-cellular Therapies, Inc.

Low-dose doxepin for treatment of sleep disorders in elderly patients

Methods of treating sleep disorders, particularly certain aspects of insomnia, in elderly patients (65 years and older) by administering initial daily dosages of doxepin of 1-3 mg. These ultra-low initial dosages are more effective in elderly versus non-elderly patients in decreasing wake time during sleep, latency to persistent sleep and wake time after sleep, and are particularly efficacious in treating those conditions in the last hour of an 8-hour sleep cycle.
Pernix Sleep, Inc.

P2x7 modulators

The present invention is directed to a compound of formula (i) or (ia) the invention also relates to pharmaceutical compositions comprising compounds of formula (i) or (ia) and methods comprising administering of compounds of formula (i) or (ia) for treating rheumatoid arthritis, osteoarthritis, psoriasis, septic shock, allergic dermatitis, asthma, allergic asthma, mild to severe asthma, steroid resistant asthma, idiopathic pulmonary fibrosis, allergic rhinitis, chronic obstructive pulmonary disease; airway hyper-responsiveness, diseases of the nervous and neuro-immune system, acute and chronic pain states of neuropathic pain, inflammatory pain, spontaneous pain, opioid induced pain, diabetic neuropathy, postherpetic neuralgia, low back pain, chemotherapy-induced neuropathic pain, fibromyalgia, diseases involved with and without neuroinflammation of the central nervous system, mood disorders, major depression, major depressive disorder, treatment resistant depression, bipolar disorder, anxious depression, anxiety, cognition, sleep disorders, multiple sclerosis, epileptic seizures, parkinson's disease, schizophrenia, alzheimer's disease, huntington's disease, autism, spinal cord injury and cerebral ischemia/traumatic brain injury, stress-related disorders, diseases of the cardiovascular, metabolic, gastrointestinal and urogenital systems such as diabetes, diabetes mellitus, thrombosis, irritable bowel syndrome, irritable bowel disease, crohn's disease, ischemic heart disease, ischaemia, hypertension, cardiovascular disease, myocardial infarction, and lower urinary tract dysfunction such as incontinence, lower urinary tract syndrome, polycystic kidney disease, glomerulonephritis, skeletal disorders, osteoporosis, osteopetrosis, and glaucoma, interstitial cystitis, cough, ureteric obstruction, sepsis, amyotrophic lateral sclerosis, chaga's disease, chlamydia, neuroblastoma, tuberculosis, and migraine.. .
Janssen Pharmaceutica Nv

P2x7 modulators

The present invention is directed to a compound of formula (i) formula (i) the invention also relates to pharmaceutical compositions comprising compounds of formula (i) and methods comprising administering to a subject at least one compound selected from compounds of formula (i) for treating diseases mediated by p2x7 receptor activity, such as rheumatoid arthritis, osteoarthritis, psoriasis, septic shock, allergic dermatitis, asthma, allergic asthma, mild to severe asthma, steroid resistant asthma, idiopathic pulmonary fibrosis, allergic rhinitis, chronic obstructive pulmonary disease; airway hyper-responsiveness, diseases of the nervous and neuro-immune system, acute and chronic pain states of neuropathic pain, inflammatory pain, spontaneous pain, opioid induced pain, diabetic neuropathy, postherpetic neuralgia, low back pain, chemotherapy-induced neuropathic pain, fibromyalgia, diseases involved with and without neuroinflammation of the central nervous system, mood disorders, major depression, major depressive disorder, treatment resistant depression, bipolar disorder, anxious depression, anxiety, cognition, sleep disorders, multiple sclerosis, epileptic seizures, parkinson's disease, schizophrenia, alzheimer's disease, huntington's disease, autism, spinal cord injury and cerebral ischemia/traumatic brain injury, stress-related disorders, diseases of the cardiovascular, metabolic, gastrointestinal and urogenital systems such as diabetes, diabetes mellitus, thrombosis, irritable bowel syndrome, irritable bowel disease, crohn's disease, ischemic heart disease, ischaemia, hypertension, cardiovascular disease, myocardial infarction, and lower urinary tract dysfunction such as incontinence, lower urinary tract syndrome, polycystic kidney disease, glomerulonephritis, skeletal disorders, osteoporosis, osteopetrosis, and glaucoma, interstitial cystitis, cough, ureteric obstruction, sepsis, amyotrophic lateral sclerosis, chaga's disease, chlamydia, neuroblastoma, tuberculosis, and migraine.. .
Janssen Pharmaceutica Nv

Potent and selective inhibitors of monoamine transporters; making; and use thereof

Disclosed herein are bisarylmethylthioacetamides and bisarylmethylthioethylamines useful as inhibitors of monoamine transporters. The compounds are potent and/or selective inhibitors of dopamine (da), serotonin (5-ht), and/or norepinephrine (ne) reuptake via their respective transporters, dat, sert and net.
The United States Of America, As Represented By Th Secretary, Department Of Health And Human Service

Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism

An implantable medical device is provided for the suppression or prevention of pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders in a patient. The implantable medical device can be a neurostimulator configured to be implanted on or near a cranial nerve to treat headache or other neurological disorders.

Compounds and pharmaceutical compositions for treating disorders associated with the 5-ht1a and 5-ht2a receptors

Alkyl-piperazine-phenyl 4 (3h)-quinazolinones compounds of general formula (i) below are provided that are pharmacologically active and able to act on the 5-ht1a and 5-ht2a serotonin receptors in a manner that promotes the control, relief or cure of disorders associated with these receptors, and pharmaceutical compositions containing the compounds for the treatment of disorders associated with these receptors. These compounds and their pharmaceutical compositions are useful in the treatment of conditions such as depression, anxiety, phobias, addictions, aggressiveness, impulsiveness, panic, psychotic, eating and sleep disorders, obsessive-compulsive disorder and female sexual dysfunctions, including loss of sexual desire, inhibition of sexual desire and absence of sexual desire, among other disorders associated with these receptors..
Ache International (bvi) Ltd.

Polymorphs and salts of a compound

Disclosed are novel crystalline polymorphic forms of 4-(4-(imidazo[1,2-b]pyridazin-2-ylmethoxy)phenyl)-2,2-dimethyl-5-(pyridin-4-yl)furan-3(2h)-one and salts thereof, methods of preparing the crystalline polymorphic forms and salts thereof, pharmaceutical compositions comprising the crystalline polymorphic forms and salts thereof, and methods of treating cns disorders, eating disorders, obesity, compulsive gambling, sexual disorders, narcolepsy, sleep disorders, diabetes, metabolic syndrome, schizophrenia, schizo-affective conditions, huntington's disease, bipolar disorders, dystonic conditions and tardive dyskinesia, or for use in smoking cessation treatment in a patient using the crystalline polymorphic forms and salts thereof.. .
Forum Pharmaceuticals Inc.

A dosage form for administering an active principle for accelerated sleep induction and/or for treating sleep disorders and/or for treating a central nervous system disorder

A dosage form for oral administration, via the mucous membranes, of an active principle for accelerated sleep induction and/or for treating sleep disorders and/or for treating a central nervous system disorder, the active principle being lipophilic or amphiphilic and being in a dissolved state that is stable and complete in a hydro-alcoholic solution having 35% to 70% by weight of ethanol and 30% to 65% by weight of water, generating nanostructures of the active principle under consideration within the hydro-alcoholic solution, thereby enabling the active principle to cross the blood-brain barrier, the active principle being in base and/or salt form and belonging to the chemical families of sleep inducers or modulators of lipophilic or amphiphilic type and of molecular weight that is less than 1000 da, the active principle being selected from the families of imidazopyridines, including zolpidem, the family of cyclopyrrolones, including eszopiclone, the family of pyrazolopyrimidines, including zaleplon, the family of benzodiazepines, including midazolam and brotizolam, the family of h1-antihistamine sedatives, including doxylamine and cyproheptadine, and/or the family of melatonin and melatonin agonists, including melatonin, ramelteon, and agomelatine, the volume of the hydro-alcoholic solution being less than or equal to 2 ml, and the active principle being present at a dosage that is less than or equal to 8 mg, all of the active principle being absorbed in transmucosal manner via the mucous membranes of the floor of the oral cavity, in particular via the gums/cheeks, via the gum area, via the cheeks, or under the tongue.. .

Devices, the treatment of sleep apnea

A medical appliance for the treatment of one or more sleep disorders such as obstructive sleep apnea in a patient, the appliance comprising: a biasing member for inserting behind and exerting a force upon the patient's soft palate or tongue, wherein the biasing member is inserted in a reduced or minimized form and then expanded or firms once in place to exert the force. The appliance may be nasally inserted or be placed through the mouth.
Lumen Devices Llc

New uses of ganaxolone

Absence epilepsy, a form of epilepsy characterized by nonconvulsive seizures, has proven to be refractive to conventional epilepsy therapies. It has been found that low doses of ganaxolone can be used to reduce absence seizures in subjects with absence epilepsy, particularly pediatric subjects.
Wisconsin Alumni Research Foundation

Systems, methods, and devices for treatment of sleep disorders

A sleep apparatus, such as a mattress, comprises a head support surface sized to support a person's head, and a torso support surface sized to support a person's torso. The head support surface is generally laterally sloped moving from a first side toward a second side of the mattress, and the torso support surface is generally laterally sloped moving from the first side toward the second side.
Hill-rom Services, Inc.



Sleep Disorders topics:
  • Sleep Disorder
  • Sleep Disorders
  • Narcolepsy
  • Schizophrenia
  • Antagonist
  • Pyrazole Derivatives
  • Movement Disorder
  • Movement Disorders
  • Eating Disorder
  • Eating Disorders
  • Neurological
  • Pharmaceutically Acceptable Salt
  • Intracranial
  • Opiate Withdrawal
  • Growth Hormone


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Sleep Disorders for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Sleep Disorders with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.6059

    file did exist - file did put2598

    3 - 1 - 51